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A Decade’s Quest for
Safer Drugs:
Congressional
Committee Green
Lights Regulation of
Drug Supply Chains
and Compounding
Manufacturers
By Mary Ann Chirba and Alice A. Noble
On May 22. 2013, the Senate Health, Education, Labor and
Pensions (HELP) Committee unanimously approved S.959,
“The Pharmaceutical Compounding Quality and
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Accountability Act,” and S.957, “The Drug Supply
and Security Act,” (now incorporated into S. 959 as an
amendment).  Congressional efforts to enact comprehensive
legislation to improve drug safety and secure the nation’s drug
supply chain have lingered for over a decade. The lack of
federal uniformity has allowed a patchwork of state legislation
to emerge, attracting the less scrupulous to those states with
the lowest security. The issue finally gained traction among
HELP Committee members when 55 people died and 741
more became ill after contracting fungal meningitis from
contaminated steroid injections made by the New England
Compounding Center (NECC). Committee member Sen. Pat
Roberts (R-KS) stated that given prior reports of problems with
NECC, this tragedy could have been averted but for a
“shocking failure to act” by NECC, state and federal regulators,
and Congress.
As NECC’s role in the meningitis outbreak came to light,gaps in
regulatory oversight did, too. The federal Food Drug and
Cosmetic Act (FDCA)[1] currently recognizes only two
categories of pharmaceutical manufacturers: commercial
pharmaceutical companies and compounding pharmacies. To
qualify as the latter under federal law, the entity must make
individual or small batch, patient-specific drugs and do so only
with a physician’s prescription for that patient.  Compounded
drugs must be either be unavailable in the commercial market
or needed in commercially unavailable doses or combinations.
The FDCA exempts such compounders from its pre-marketing
requirements applicable to commercially manufactured drugs.
Thus, federal law clearly covers commercial pharmaceutical
manufacturers, state law just as clearly oversees and licenses
pharmacies but as the NECC case demonstrates, there is
nothing clear about the responsibility for inspecting, licensing or
otherwise overseeing compounders that do not fill prescriptions
on a per patient basis.
Instead of compounding in response to an individual
prescription, the New England Compounding Center made
large batches of drugs for institutional buyers such as hospitals.
Many of its drugs were commercially unavailable but some
were knock-offs of marketed FDA-approved drugs – a practice
which is clearly unauthorized. NECC’s business model was
certainly not unique; neither was the limited and erratic
response of state and federal regulators to complaints about
the facility’s unsafe manufacturing practices. Congress knew
that large-scale compounders existed along with concerns
about their safety. Several members of the Senate HELP
Committee had worked on curative legislation for over ten
years, but made few inroads until the NECC crisis prompted
the  HELP Committee to shift from park into drive.
In its current form, S. 959’s  Pharmaceutical Compounding
Quality and Accountability Act  pursues two overriding
objectives: clarifying lines of regulatory authority and
accountability, and ensuring that a compounded drug is what it
says.  As they have been, traditional compounders would
continue to be regulated by state law and commercial
manufacturers would remain subject to federal law. To these
two categories of drug manufacturers, however, S.959 would
amend the FDCA to add a third type of drug manufacturer to fit
the NECC-type mode.  “Compounding manufacturers” that
compound sterile drugs before receiving a prescription, and
ship in interstate commerce (excluding shipments within a
hospital system) would now be regulated exclusively by federal
law. The bill permits States to impose heavier requirements,
but  preempts state laws that do less.
While federally regulated, the compounding manufacturer
would need to have a state-licensed pharmacist directly
oversee its products. In addition, the compounding
manufacturer would be subject to FDA inspection and pay a
registration fee to offset the cost of the inspection program.
Compounding manufacturers with gross sales of $1m or more
will pay an annual $15,000 registration fee while those with
lower sales will pay $5000.  Reporting requirements include
submitting  semi-annual reports of drugs sold, and informing
the FDA of serious adverse events within 15 days. The
compounding manufacturer cannot wholesale its products and
must label them as “not for resale.” Failing to pay the annual
registration fee, selling drugs that are not for resale, and selling
drugs that are already marketed as FDA-approved will all be
treated as unlawful drug misbranding. Through notice and
comment rulemaking, the agency will develop a list of drugs
that may not be compounded due, for example, to their
complex dosage forms or their use of biologics. This list would
be updated at least every 5 years.
State-regulated, traditional compounders would remain  exempt
from the FDCA Good Manufacturing Practices[2]  that apply to
commercial manufacturers. Although compounding
manufacturers will also be exempt from the FDCA’s CGMPs,
the FDA will develop GMPs that are suitable to this category of
manufacturer.
Dealing with drug compounding was not the HELP Committee’s
only concern. The national attention on drug safety spurred the
Committee to act on another decade-long  effort to improve the
drug supply chain. S.957’s “Drug Supply Chain Security
Act,” (now incorporated into S. 959), updates a system that
has remained unchanged for 25 years despite quantum
improvements in technology and steady increases in security
threats. As Senator Michael Bennet (D-CO)  observed, “we
know more from a bar code on a gallon of milk than we do on a
bottle of pills that could mean the difference between life and
death for patients and families.”
To make the drug supply chain safer, the so-called “Track and
Trace” bill would phase-in an electronic, inter-operable, unit
level system designed to, again in Senator Benett’s words,
provide “certainty and most  importantly, get bad actors out of
the drug supply chain. It will give peace of mind to the everyday
family picking up their prescription at the drug store.” Senator
Barbara Mikulski (D-MD) explained that the FDCA’s current
drug pre-marketing requirements focus on a drug’s safety and
efficacy at the point of manufacture. However, once a drug is
released to the supply chain, the statute and the agency do
little to prevent it from being contaminated, tampered with, or
replaced by counterfeit drugs after leaving the manufacturer. As
a result, the safety of clinical practice is threatened and patients
cannot be confident that the medication in their home is the
safe and effective one that their doctor prescribed.
To fill this gap, the Track and Trace law would impose a blend
of licensing, reporting, labeling and coding requirements on
each “trading partner” at each link in the supply chain, from the
manufacturer to the patient. Its major components can be
summarized as follows:
1. Drugs: The Drug Supply Chain Act covers prescription
drugs in their finished dosage form that are ready to be
dispensed or administered to the patient without
substantial further remanufacturing. It does not cover
blood, blood products, compressed medical gases or other
specified products.
2. Licensing: Only authorized “trading partners” can
handle drugs in the supply chain from initial manufacture to
the patient. Manufacturers and re-packagers must register
with the FDA. Federal licensing is required of wholesale
distributors and third party logistics providers (such as
warehousing or transporting without assuming ownership).
State licensing will continue to cover pharmacies and other
persons authorized to dispense or administer drugs to the
patient.
3. Individual Product Identifiers: Each unit of each
drug must carry a product identifier that can be read by
both person and machine and include a standardized
medical identifier for the product; lot number; expiration
date; and an individualized, standardized numerical
identifier for each unit or package of a uniquely coded,
specific product.
4. Transaction History: Each transfer of the product
during the process of moving from the manufacturer to the
patient or return from the patient to the manufacture, must
be documented with a paper or electronic form tracking
each transaction and prior transactions (or links in the
supply chain), starting with the manufacturer. It must
denote the business names and addresses of each party
to each transaction, and the date and shipment date of
each transaction. In addition, it must state the  product’s
name, strength, dosage, numerical drug code, container
size, and lot number.
5. Suspect Products include those that are potentially
counterfeit, diverted, stolen, adulterated, fraudulent, or
otherwise unfit for distribution and must be reported to the
FDA.
6. Secure Electronic Databases must be
established or used by each trading partner to track and
trace drugs, through each step of the supply chain.
All of these features will be used to develop a secure,
interoperable electronic data exchange system to facilitate the
exchange of information among all trading partners in order to
track and trace each package through each link in the drug
supply chain. This will also enable the FDA to respond quickly
and appropriately to products that are known or suspected to
be unsafe, and do so even at the individual package level.
In drafting both the compounding manufacturer and the drug
supply bills, the HELP Committee worked closely with
numerous stakeholders including patients and consumers,
doctors and hospitals, pharmacies and manufacturers, and
state and federal regulators. Although it approved the bills
unanimously, the Committee acknowledged that S.959 (which
again, incorporates S. 957) may face significant obstacles as it
progresses to the Senate floor for debate and voting and, if
successful, to the full Congress for more of the same. If
ultimately enacted, a sizeable hurdle will remain: obtaining full
funding. Each initiative will be costly, particularly developing
and implementing a nation-wide secure, interoperable
electronic system for tracking and tracing drugs at the package
level. Hopefully, however, those costs will be offset by
reductions in the many costs generated by unsafe drugs, the
largest  of which are obviously human lives. In the words of 
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Senator Burr, the bill was a “key milestone” for patients and
drug supply stakeholders.
The HELP Committee seems confident that S.959  as amended
to include S.957 will ultimately be signed into law given the
gathering momentum for its passage. The bill’s supporters will
hope Senator Mikulski was right when she stated that passage
is “achievable [and] doable” because it makes sense, has
bipartisan support, and “solves a problem of compelling human
need.” Therefore, if it does not pass, the legislators may need
to answer to their constituents because, as recognized by
Senator Bennet, “though what we’re doing in some ways is
historic, I think most people that we represent have an
expectation that this has already been done.”
[Cross-posted from HealthLawProf Blog]
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